Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies

Detalles Bibliográficos
Autores principales: Kater, Arnon P., Tonino, Sanne H., Spiering, Marjolein, Chamuleau, Martine E. D., Liu, Roberto, Adewoye, Adeboye Henry, Gao, Jie, Dreiling, Lyndah, Xin, Yan, Doorduijn, Jeanette K., Kersten, Marie José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809482/
https://www.ncbi.nlm.nih.gov/pubmed/29434192
http://dx.doi.org/10.1038/s41408-018-0055-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809482/
https://www.ncbi.nlm.nih.gov/pubmed/29434192
http://dx.doi.org/10.1038/s41408-018-0055-x

Ejemplares similares